Note 5—Certain Balance Sheet Accounts

Receivables

Grant and other receivables consisted of the following:


	December 31,
	2011		2010
	(in thousands)
Grant and GPCR funding receivable	$	862	$	1,144
Other receivables		14		335

Grant and other receivables	$	876	$	1,479

On October 29, 2010, we were awarded grants totaling $1.7 million from the U.S. government pursuant to the U.S. Qualifying Therapeutic Discovery Project Program. We received $1.5 million in 2010, which was recorded as other income. We received the remaining $236,000 in May 2011.

Property and Equipment

Property and equipment consisted of the following:


	December 31,
	2011			2010
	(in thousands)
Computer equipment	$	490		$	518
Computer software		419			414
Office equipment and furniture		284			284
Leasehold improvements		304			310
Capital lease equipment		201			201
Laboratory equipment		1,520			1,978

Total		3,218			3,705
Less accumulated depreciation and amortization		(2,479	)		(2,083	)

Property and equipment, net	$	739		$	1,622

Our property and equipment have lives that range from three to five years with the exception of the leasehold improvements that are limited to the lesser of the term of the lease or five years. For the years ended December 31, 2011, 2010 and 2009, depreciation expense was $435,000, $472,000 and $392,000, respectively.

Accrued Expenses

Accrued expenses consisted of the following:


	December 31,
	2011		2010
	(in thousands)
Clinical trials	$	3,532	$	2,548
Contract research		694		351
Employee compensation		364		974
Other accruals		750		694

Accrued expenses	$	5,340	$	4,567

Accumulated Other Comprehensive Loss

Comprehensive loss is comprised of net loss and certain changes in equity that are excluded from net loss. Our only component of other comprehensive loss is unrealized gains (losses) on available-for-sale securities. There was no accumulated other comprehensive loss as of December 31, 2011 as we sold the underlying available-for-sale securities in May 2010.